MAP2K7 and plasma cell myeloma: In myeloma, the combination of BRAF and MEK co‐inhibition (vemurafenib and cobimetinib, dabrafenib and trametinib) has been reported in four patients with advanced MM and BRAF p.V600E mutation and resulted in transient partial response [7, 8].